FDA Warning Letter · #721817
Peaks — FDA Warning Letter (February 20, 2026)
Legal name: Peaks Curative, LLC
In plain English
Marketing claimsFDA’s letter to Peaks cites false or misleading claims about semaglutide products, which FDA says made them misbranded. The letter on fda.gov lists the specific claims.
What it means for you
This letter is about how the products were advertised. It is not a finding that a specific product or batch was contaminated or unsafe. Compounded GLP-1s are not FDA-approved, so if you use this company, ask which pharmacy makes your medication.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peaks-curative-llc-dba-peaks-721817-02202026
Letter details
- Company
- Peaks Curative, LLC (dba Peaks)
- Letter number
- #721817
- Issue date
- February 20, 2026
- Subject
- False & Misleading Claims/Misbranded
What FDA warning letters mean
A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.
A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.
For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.
What this letter means if you use compounded GLP-1s
A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects Peaks to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed.
Advertising is the subject of this letter, so it helps to know what the approved products are. Our semaglutide overview page lists the brand-name versions FDA has reviewed, and our patient guide to compounded versus brand-name GLP-1s walks through the trade-offs between the two.
Other warning letters in our database
- Zeuss — February 20, 2026
- WeightCare — February 20, 2026
- VIV RX — February 20, 2026
- Strut — February 20, 2026
- Refills Health — February 20, 2026
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory